Phase 2 Myeloma Trial, Recruiting NCT07053436 Sponsor: Multiple Myeloma Research Consortium Condition: Myeloma
Back to Myeloma

Phase 2 Myeloma Trial, Recruiting

NCT07053436
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have signed a written consent form
  • You are 18 years of age or older
  • You have been newly diagnosed with multiple myeloma that has been confirmed by a specialist, you are well enough to receive a stem cell transplant, and your myeloma is considered "high-risk" based on specific genetic features or disease characteristics (confirm with trial site for details on which features qualify)
  • You have received no more than 2 cycles of standard starting treatment (induction therapy) for your multiple myeloma
  • Your myeloma can be measured through specific blood, urine, or bone marrow tests at the time of diagnosis
  • Your general health and ability to carry out daily activities meets a certain minimum level (a score of 0–2 on a standard scale used by doctors)
  • Your blood cell counts, liver, and kidneys are working well enough to meet the trial's minimum requirements (confirm with trial site for exact values)
  • If you could become pregnant, you have had a negative pregnancy test within 72 hours before starting trial treatment
  • If you could become pregnant, you are willing to use highly effective birth control from the start of the trial until 90 days after your last dose
  • If you are a man with a partner who could become pregnant, you are willing to use highly effective birth control from the start of the trial until 90 days after your last dose; if your partner is pregnant, you must agree to use a condom
  • If you have a history of heart problems or have been treated with medicines that can affect the heart, your heart function must be at a level where ordinary activity causes only slight limitations (confirm with trial site)
  • You have had or currently have another type of cancer, as long as it is unlikely to affect how this trial works or your safety
  • You have HIV but are on effective treatment and your virus levels are undetectable within the last 6 months
  • You have chronic hepatitis B but are on treatment that keeps the virus undetectable
  • You have had hepatitis C and it has been successfully treated and cured, or you are currently being treated and your virus levels are undetectable
  • You are willing and able to follow all the requirements of the trial

Who may not be able to join:

  • You have a serious condition affecting major organs at the same time, such as POEMS syndrome or a condition called AL amyloidosis that is causing symptoms in a major organ
  • You have a known allergy or serious reaction to any of the medicines used in this trial or their ingredients
  • You have spinal cord compression affecting the whole spinal cord, or your myeloma has spread to your brain or central nervous system
  • You have a condition where myeloma cells are in the fluid surrounding your brain and spinal cord (leptomeningeal disease)
  • You have had an organ or tissue transplant from another person and have a related immune condition (called chronic GVHD) requiring a higher dose of steroid medicines
  • You currently have an active infection that requires treatment
  • You have any other medical condition, past treatment, or lab result that the trial doctor believes could interfere with the trial or may not be in your best interest
  • You have a psychiatric condition or substance use problem that could prevent you from following the trial's requirements
  • You do not have the legal ability to make your own decisions about participating
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hearn Jay Cho, MD, PhD, Multiple Myeloma Research Foundation

Phone: 2036520457

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Multiple Myeloma Research Consortium
Registry
ClinicalTrials.gov
Start date
30 April 2026
Est. completion
1 October 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sustained measurable residual disease (MRD) negativity; Progression Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov